Pharmacological properties Asacol 800 mg:
mesalazine – 5-aminosalicylic acid, anti-inflammatory effect. The mechanism of action is still not entirely established. Mesalazine inhibits the migration of polymorphonuclear leukocytes and the activity of lipoxygenase. As a consequence, decreases the synthesis of leukotrienes, inflammatory macrophages in the intestinal wall. Mesalazine inhibits platelet activating factor, is also an antioxidant: it reduces the synthesis of substances that contain active oxygen free radicals, and associates.
Asacol tablets are coated with a polymer membrane that allows the release of the active substance in the lower ileum and colon, which are the main cells of inflammation. The tablets is chosen so as to minimize the absorption of mesalazine in the gastrointestinal tract. Absorption after oral administration – 26%. 74% of the administered dose remains in the lower ileum and colon, and rectum, providing there is a local inflammatory effect. Metabolism by the liver and intestinal mucosa, forms an inactive metabolite N-acetyl-5-amino salicylic acid. The half-life of less than an hour. Excretion occurs mainly in the faeces and urine in unchanged form and in the form of N-acetyl-5-amino salicylic acid.
INDICATIONS Asacol 800 mg:
Ulcerative colitis: treatment of mild to moderate degree; maintenance therapy in remission.
Crohn’s disease: maintenance treatment in remission.
APPLICATION Asacol 800 mg:
ulcerative colitis: the disease of mild to moderate severity daily dose of 2,4-4,8 g, distributed in several stages.
Supportive care in remission daily dose – 1.2-2.4 g, divided into several stages.
Crohn’s disease: supportive care in remission dose is 2.4 g, distributed in several stages.
Doses for adults and children alike.
Patients older age group drug prescribed with caution and only when you save normal kidney function.
Tablets are taken before eating, swallowing them whole, without breaking the and not liquid.
Contraindications Asacol 800 mg:
hypersensitivity to salicylates or any component of the drug, expressed in human liver and kidney, gastric and duodenal ulcers, increased bleeding tendency, and children under the age of 2 years.
SIDE EFFECTS Asacol 800 mg:
In some cases, hypersensitivity reactions are observed: hyperthermia, bronchoconstriction, hair loss (1 in 1000-10 000 patients). Hair loss may also be a manifestation of chronic inflammatory bowel disease. Rare – abdominal pain and diarrhea.
Very rarely experience side effects from the following systems and organs: blood system and lymphatic system, cardiovascular system, musculoskeletal system, respiratory system, gastrointestinal tract, skin and its appendages, the urinary system.
Precautions Asacol 800 mg:
Not recommended for patients with impaired renal function. Precautions should be taken in patients with high concentrations of blood urea and proteinuria. Careful monitoring of the patient is required for respiratory disorders, especially with the appearance of asthmatic attacks.
It is recommended to monitor renal function and blood tests for all patients before treatment Asacol, as well as during treatment according to the scheme within 14 days of therapy, then 2-3 more times with a 4-week intervals. Under normal results of the control analysis is repeated on a quarterly basis. In the presence of impaired performance tests need further investigation.
During pregnancy and lactation. Asacol is prescribed only if indicated, given the benefit of treatment for the mother and the potential risk to the fetus.
It has no effect on driving ability and mechanisms.
INTERACTION Asacol 800 mg:
while the application of mesalazine and digoxin reduced the absorption of digoxin. Under the action of mesalazine can increase the activity of azathioprine and imunodepressivnaya mercaptopurine. Before starting combination therapy should be monitored blood formula, especially white blood cell count, blood tests periodically during treatment.
Mesalazine, while the application may reduce the effectiveness of probenecid and sulfinpyrazone, spironolactone, furosemide and.
Virazhennost side effects of GCS with respect to the gastrointestinal tract in the general application of mesalazine increased.
